Rosenbluh, J., H., X., Harrington, W., Gill, S., et al. (2017). Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nature Communications. In press.
Ilic, N., Birsoy, K., Aguirre, A.J., et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci USA. 2017; 114, E3434-E3443.
Aguirre, A.J., Meyers, R.M., Weir, B.A., et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 Aug;6(8):914-29.
Howard, T.P., Vazquez, F., Tsherniak, A., et al. Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol. 2016.
Kryukov, G.V., Wilson, F.H., Ruth, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351, 1214-1218.
Francisca Vazquez, Ph.D.
Francisca Vazquez is a senior group leader in the Cancer Dependency Map project. She supports the development of large-scale datasets in cancer cell lines aimed to identify essential genes and small molecule dependencies at the molecular markers that predict their sensitivity. Her goal is to identify the landscape of cancer targets for therapeutic development.
Vazquez works closely with institute member William Hahn and Cancer Program director Todd Golub on the scientific planning and strategic execution of the Cancer Dependency Map initiative. In this role, she coordinates a large interdisciplinary team of project managers, bench scientists, and computational biologists that use state-of-the-art genome-scale functional genomics, including CRISPR and high-throughput small molecule screening technologies, to identify and validate cancer vulnerabilities across a large number of tumor types. She also supports key Cancer Dependency Map flagship projects by catalyzing collaborations both within the Broad and with key external collaborators to rapidly identify and de-risk new therapeutic opportunities in areas of high interest.
Prior to joining the Broad Institute in 2011, Vazquez studied cancer metabolism as a research scientist at Dana-Farber Cancer Institute (DFCI). She earned her Ph.D. from the University of Illes Balears in Spain while performing most of her work as a visiting student at Beth-Israel Deaconess Medical Center, and conducted postdoctoral research on tumor suppressor genes at DFCI.